66. IgA nephropathy Clinical trials / Disease details


Clinical trials : 275 Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05083364
(ClinicalTrials.gov)
February 2, 20228/10/2021Study of ARO-C3 in Adult Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria and Complement-Mediated Renal DiseaseA Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and/or Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria and Adult Patients With Complement-Mediated Renal DiseaseParoxysmal Nocturnal Hemoglobinuria;C3 Glomerulopathy;IgA NephropathyDrug: ARO-C3;Drug: PlaceboArrowhead PharmaceuticalsNULLRecruiting18 Years70 YearsAll84Phase 1Australia;Korea, Republic of;New Zealand;Thailand